SOURCE: CannaPharmaRx, Inc.

CannaPharmaRx, Inc. Logo

June 17, 2015 11:32 ET

CannaPharmaRx to Exhibit at the Cannabis World Congress & Business Expo in NYC

CARNEYS POINT, NJ--(Marketwired - June 17, 2015) - CannaPharmaRx, Inc. (OTCQB: CPMD), a leader in the research, development, and commercialization of cannabinoid-based drug products, announced today that it will be exhibiting at the 2nd Annual Cannabis World Congress & Business Expo. The conference will be held at the Jacob Javits Center in New York, NY from Wednesday, June 17 through Friday, June 19. CannaPharmaRx will exhibit in booth # 316.

The Cannabis World Congress & Business Expo is the definitive business event for the cannabis industry. Exhibitors and sponsors bring cutting-edge solutions to owners and managers of businesses in this fast-growing industry, and a wealth of opportunity and knowledge to those looking to enter the market with potential partners and investors. This year, over 90 business will be showcasing the latest technologies, solutions, and resources of the cannabis industry.

About CannaPharmaRx, Inc.
CannaPharmaRx, Inc. is an early-stage pharmaceutical company whose purpose is to advance cannabinoid research and discovery using proprietary formulation and drug delivery technology currently in development. Cannabinoids are a class of chemicals that, once ingested, are active in humans and animals through the "endocannabinoid system" -- one of the most widely expressed system of receptors in the human body. CannaPharmaRx is currently focused on targeting disease states where its delivery systems can have optimal impact with therapeutic differentiation among alternative cannabinoid therapies, including: insomnia, neurological disorders, oncology, infectious disease, pain management, inflammatory disease, gastrointestinal disorders and ophthalmology. For more information, please visit www.CannaPharmaRx.com.

Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated," and "intend" among others. These forward-looking statements are based on CannaPharmaRx's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to: substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical products under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that matters discussed in this press release will be completed or successful. CannaPharmaRx does not undertake any obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in CannaPharmaRx's Annual Report on Form 10-K for the year ended December 31, 2014 and other periodic reports filed with the Securities and Exchange Commission.

Image Available: http://www.marketwire.com/library/MwGo/2015/6/17/11G045108/Images/cannabis-730781750306.jpg

Contact Information